Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:ceased_operations |
2019
|
| gptkbp:foundedIn |
gptkb:Basingstoke,_England
1986 |
| gptkbp:headquartersLocation |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shire (acquired)
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
gptkb:Angus_Russell
gptkb:Flemming_Ørnskov gptkb:Matthew_Emmens gptkb:Susan_Kilsby |
| gptkbp:netIncome |
$4.27 billion (2017)
|
| gptkbp:notableProduct |
gptkb:Adderall
gptkb:Cinryze gptkb:Firazyr gptkb:Lialda gptkb:Vyvanse Elaprase Replagal |
| gptkbp:numberOfEmployees |
~24,000 (2017)
|
| gptkbp:parentCompany |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:publiclyTraded |
gptkb:London_Stock_Exchange
gptkb:NASDAQ |
| gptkbp:revenue |
$15.16 billion (2017)
|
| gptkbp:specializesIn |
immunology
neuroscience hematology rare diseases gastrointestinal diseases |
| gptkbp:bfsParent |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:bfsLayer |
7
|